Solana Company (HSDT) Q4 2024 Earnings Report

Solana Company reported QQ4 2024 revenue of $152,000, up 13.4% year over year, with a meaningful QoQ surge from $51,000 in Q3 2024 to $152,000 in Q4 2024 (≈198% QoQ). Despite this top-line uptick, Solana generated a pre-tax loss of $3.928 million and a net loss of $3.928 million for the quarter, translating to an EPS of −$1.45. The quarter featured a gross loss of $2,000 on $152,000 of revenue, yielding a gross margin of −1.32%. Operating expenses remained a disproportionate burden, with R&D of $924,000 and selling, general and administrative expenses of $2.178 million, contributing to an EBITDA of −$3.095 million and an operating loss of −$3.147 million. The company also recognized a net other expense of $0.781 million, compounding the quarterly bottom-line pressure.

Liquidity remained tight. The company ended QQ4 2024 with cash and cash equivalents of $1.089 million, a decline from $3.469 million at the prior period start, reflecting a net cash burn from operations of approximately $2.378 million and a total net cash decrease of about $2.38 million for the quarter. Free cash flow was negative $2.378 million. The balance sheet shows total assets of $3.542 million and total liabilities of $2.483 million, yielding stockholders’ equity of about $1.059 million. Notably, retained earnings are deeply negative at approximately −$171.699 million, underscoring a sustained deficit profile. Short-term debt stood at $24,000 and total debt at $12,000, producing a net debt position of roughly −$1.076 million, i.e., cash exceeds debt.

From a risk-reward perspective, Solana remains an early-stage clinical/digital-health device concept with substantial execution risk. The quarterly improvement in gross margin to −1.3% from much deeper quarterly losses on prior quarters indicates some cost containment or mix improvement, but profitability remains a long way off. The compelling question for investors is whether Solana can achieve meaningful revenue momentum, secure scalable partnerships or licensing arrangements, and convert clinical or regulatory milestones into durable margin expansion. Absent a material shift in revenue scale or a capital-raising event that funds near-term burn, liquidity runway and financing risk will remain central to the investment thesis.